Literature DB >> 19630571

Evolving treatment of advanced colon cancer.

Neil H Segal1, Leonard B Saltz.   

Abstract

Colorectal cancer is a common malignancy worldwide. Despite significant developments in the treatment of this disease, it still causes considerable morbidity and mortality. Recent advances include both newer cytotoxic chemotherapies and novel biologic agents. Although overall progress has been more modest than had been hoped, substantial benefits have been achieved for some patients, and the number of treatment options has substantially increased. Perhaps most importantly, treatment regimens can now be selected and tailored toward the individual patient following an informed discussion between the patient and the treating oncologist. We present in detail these recent advances and provide some insight into several promising future strategies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19630571     DOI: 10.1146/annurev.med.60.041807.132435

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  57 in total

1.  MAPK14/p38α confers irinotecan resistance to TP53-defective cells by inducing survival autophagy.

Authors:  Salome Paillas; Annick Causse; Laetitia Marzi; Philippe de Medina; Marc Poirot; Vincent Denis; Nadia Vezzio-Vie; Lucile Espert; Hayat Arzouk; Arnaud Coquelle; Pierre Martineau; Maguy Del Rio; Sophie Pattingre; Céline Gongora
Journal:  Autophagy       Date:  2012-05-31       Impact factor: 16.016

2.  Natural killer cells inhibit oxaliplatin-resistant colorectal cancer by repressing WBSCR22 via upregulating microRNA-146b-5p.

Authors:  Haiyan Zhao; Wuyun Su; Qingmei Kang; Ze Xing; Xue Lin; Zhongjun Wu
Journal:  Am J Cancer Res       Date:  2018-05-01       Impact factor: 6.166

3.  CXCL13-CXCR5 axis promotes the growth and invasion of colon cancer cells via PI3K/AKT pathway.

Authors:  Zhenyu Zhu; Xukui Zhang; Hongliang Guo; Ling Fu; Ganlin Pan; Yinggang Sun
Journal:  Mol Cell Biochem       Date:  2014-12-05       Impact factor: 3.396

4.  Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis.

Authors:  Dongshi Chen; Liang Wei; Jian Yu; Lin Zhang
Journal:  Clin Cancer Res       Date:  2014-04-24       Impact factor: 12.531

Review 5.  Targeted therapy in head and neck cancer.

Authors:  S K Kundu; M Nestor
Journal:  Tumour Biol       Date:  2012-02-29

Review 6.  Molecular targeted therapies in head and neck cancer--an update of recent developments-.

Authors:  Martin Goerner; Tanguy Y Seiwert; Holger Sudhoff
Journal:  Head Neck Oncol       Date:  2010-04-14

Review 7.  The Met oncogene and basal-like breast cancer: another culprit to watch out for?

Authors:  Stefania Gastaldi; Paolo M Comoglio; Livio Trusolino
Journal:  Breast Cancer Res       Date:  2010-08-23       Impact factor: 6.466

8.  Methylation status of the APC and RASSF1A promoter in cell-free circulating DNA and its prognostic role in patients with colorectal cancer.

Authors:  Dimitrios Matthaios; Ioanna Balgkouranidou; Anastasios Karayiannakis; Helen Bolanaki; Nikolaos Xenidis; Kyriakos Amarantidis; Leonidas Chelis; Konstantinos Romanidis; Aikaterini Chatzaki; Evi Lianidou; Grigorios Trypsianis; Stylianos Kakolyris
Journal:  Oncol Lett       Date:  2016-06-01       Impact factor: 2.967

9.  Addition of bromelain and acetylcysteine to gemcitabine potentiates tumor inhibition in vivo in human colon cancer cell line LS174T.

Authors:  Ahmed H Mekkawy; Krishna Pillai; Samina Badar; Javed Akhter; Kevin Ke; Sarah J Valle; David L Morris
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

10.  Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients.

Authors:  I Zlobec; F Molinari; M Kovac; M P Bihl; H J Altermatt; J Diebold; H Frick; M Germer; M Horcic; M Montani; G Singer; H Yurtsever; A Zettl; L Terracciano; L Mazzucchelli; P Saletti; M Frattini; K Heinimann; A Lugli
Journal:  Br J Cancer       Date:  2009-11-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.